Management of malignant pleural mesothelioma

Asia-Pacific Journal of Clinical Oncology

Volumn 3, Issue 4, 2007, Pages 177-186

  Nowak, Anna K ^a   Bydder, Sean ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

Antineoplastic therapy; Cisplatin; Malignant mesothelioma; Pemetrexed; Radiotherapy

Indexed keywords

AMMINEDICHLORO(2 METHYLPYRIDINE)PLATINUM; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CROCIDOLITE; FOLIC ACID ANTAGONIST; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; LOCAL ANESTHETIC AGENT; MESOTHELIN; MITOMYCIN C; NARCOTIC ANALGESIC AGENT; NAVELBINE; OXALIPLATIN; PEMETREXED; RALTITREXED; TALC; VINBLASTINE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER DIAGNOSIS; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER SURVIVAL; CATHETERIZATION; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DEHYDRATION; DIARRHEA; DRUG CHOICE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EARLY DIAGNOSIS; FEBRILE NEUTROPENIA; HISTOPATHOLOGY; HUMAN; LUNG RESECTION; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OCCUPATIONAL HAZARD; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PLEURODESIS; PRIORITY JOURNAL; REVIEW; THORAX RADIOGRAPHY; TUMOR BIOPSY; VITAMIN SUPPLEMENTATION;

EID: 36749099529     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2007.00116.x     Document Type: Review

References (73)

1. Bourdes V, Boffetta P, Pisani P. Environmental exposure to asbestos and risk of pleural mesothelioma: Review and meta-analysis. Eur J Epidemiol 2000; 16: 411-17.
2. Nurminen M, Karjalainen A, Takahashi K. Estimating the induction period of pleural mesothelioma from aggregate data on asbestos consumption. J Occ Envir Med 2003; 45: 1107-15.
3. Peto J, Hodgson JT, Matthews FE, Jones JR. Continuing increase in mesothelioma mortality in Britain. Lancet 1995; 345: 535-9.
4. Leigh J, Davidson P, Hendrie L, Berry D. Malignant mesothelioma in Australia, 1945-2000. Am J Indust Med 2002; 41: 188-201.
5. Price B. Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol 1997; 145: 211-8.
6. Kazan-Allen L. Asbestos and mesothelioma: Worldwide trends. Lung Cancer 2005; 49 (Suppl. 1): S3-8.
7. Takahashi K, Karjalainen A. A cross-country comparative overview of the asbestos situation in ten Asian countries. Int J Occup Med Environ Health 2003; 9: 244-8.
8. Chan K, Tan KL, Lee HS, Eng P. Malignant mesothelioma: Experience at the Singapore General Hospital. Ann Acad Med Singapore 2003; 32: 388-91.
9. Paek D. Asbestos problems yet to explode in Korea. Int J Occup Med Environ Health 2003; 9: 266-71.
10. Furuya S, Natori Y, Ikeda R. Asbestos in Japan. Int J Occup Med Environ Health 2003; 9: 260-5.
11. Joshi TK, Gupta RK. Asbestos-related morbidity in India. Int J Occup Med Environ Health 2003; 9: 249-53.
12. Dave SK, Beckett WS. Occupational asbestos exposure and predictable asbestos-related diseases in India. Am J Indust Med 2005; 48: 137-43.
13. Joshi TK, Gupta RK. Asbestos in developing countries: Magnitude of risk and its practical implications. Int J Occup Med Environ Health 2004; 17: 179-85.
14. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P etal. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-44.
15. Musk AW, Woodward SD. Conventional treatment and its effect on survival of malignant pleural mesothelioma in Western Australia. Aust NZ J Med 1982; 12: 229-32.
16. Sterman DH, Kaiser LR, Albelda SM. Advances in the treatment of malignant pleural mesothelioma. Chest 1999; 116: 504-20.
17. Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma. A review. J Clin Oncol 1996; 14: 1007-17.
18. Attanoos RL, Gibbs AR. Pathology of malignant mesothelioma. Histopathology 1997; 30: 403-18.
19. Segal A, Whitaker D, Henderson D, Shilkin K. Pathology of mesothelioma. In: Robinson BWSCP, eds., editor. Mesothelioma. London: Martin Dunitz; 2002. p. 143-84.
20. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N etal. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003; 362 (9396): 1612-16.
21. Van Schil P. Malignant pleural mesothelioma: Staging systems. Lung Cancer 2005; 49 (Suppl. 1): S45-8.
22. Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM etal. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients. J Thorac Cardiovasc Surg 1999; 117: 54-63; discussion 63-5.
23. British Thoracic Society Standards of Care C. Statement on malignant mesothelioma in the United Kingdom. Thorax 2001; 56: 250-65.
24. Butchart EG. Contemporary management of malignant pleural mesothelioma. Oncologist 1999; 4: 488-500.
25. Alvarez JM, Ha T, Musk W, Robins P, Price R, Byrne MJ. Importance of mediastinoscopy, bilateral thoracoscopy, and laparoscopy in correct staging of malignant mesothelioma before extrapleural pneumonectomy. J Thorac Cardiovasc Surg 2005; 130: 905-6.
26. Pass HI, Kranda K, Temeck BK, Feuerstein I, Steinberg SM. Surgically debulked malignant pleural mesothelioma: Results and prognostic factors. Ann Surg Oncol 1997; 4: 215-22.
27. Rusch VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial. [see comment]. J Thorac Cardiovasc Surg 1991; 102: 1-9.
28. Baldini EH, Recht A, Strauss GM, DeCamp MM, Jr., Swanson SJ, Liptay MJ etal. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 1997; 63: 334-8.
29. Yajnik S, Rosenzweig KE, Mychalczak B, Krug L, Flores R, Hong L etal. Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2003; 56: 1319-26.
30. Senan S, van de Pol M. Considerations for post-operative radiotherapy to the hemithorax following extrapleural pneumonectomy in malignant pleural mesothelioma. Lung Cancer 2004; 45 (Suppl. 1): S93-6.
31. Ahamad A, Stevens CW, Smythe WR, Liao Z, Vaporciyan AA, Rice D etal. Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest. Cancer J 2003; 9: 476-84.
32. Ahamad A, Stevens CW, Smythe WR, Vaporciyan AA, Komaki R, Kelly JF etal. Intensity-modulated radiation therapy: A novel approach to the management of malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2003; 55: 768-75.
33. Forster KM, Smythe WR, Starkschall G, Liao Z, Takanaka T, Kelly JF etal. Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: Clinical implementation. Int J Radiat Oncol Biol Phys 2003; 55: 606-16.
34. Allen AM, Czerminska M, Janne PA, Sugarbaker DJ, Bueno R, Harris JR etal. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys 2006; 65: 640-5.
35. Aelony Y, Yao JF. Prolonged survival after talc poudrage for malignant pleural mesothelioma: Case series. Respirology 2005; 10: 649-55.
36. Tsang V, Fernando HC, Goldstraw P. Pleuroperitoneal shunt for recurrent malignant pleural effusions. Thorax 1990; 45: 369-72.
37. Ung YC, Yu E, Falkson C, Haynes AE, Stys-Norman D, Evans WK etal. The role of radiation therapy in malignant pleural mesothelioma: A systematic review. Radiother Oncol 2006; 80: 13-18.
38. Senan S. Indications and limitations of radiotherapy in malignant pleural mesothelioma. Curr Opin Oncol 2003; 15: 144-7.
39. Davis SR, Tan L, Ball DL. Radiotherapy in the treatment of malignant mesothelioma of the pleura, with special reference to its use in palliation. Australas Radiol 1994; 38: 212-14.
40. Boutin C, Rey F, Viallat JR. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest 1995; 108: 754-8.
41. Murphy DF. Interpleural analgesia. Br J Anaesthesia 1993; 71: 426-34.
42. van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005; 23: 6881-9.
43. Nowak AK, Byrne MJ, Williamson R, Ryan G, Segal A, Fielding D etal. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 2002; 87: 491-6.
44. Nowak AK, Stockler MR, Byrne MJ. Use of the EORTC QLQ-C30 and LC13 in a study of combination chemotherapy for pleural malignant mesothelioma: feasibility, validity and baseline HRQL. J Clin Oncol 2004; 22: 3172-3180.
45. O'Brien MER, Watkins D, Ryan C, Priest K, Corbishley C, Norton A et al. A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: The MED trial. Ann Oncol. 2006 Feb; 17: 270-5.
46. Gralla RJ, Hollen PJ, Liepa AM, Symanowski J, Boyer M, Abraham R et al. Improving quality of life in patients with malignant pleural mesothelioma: Results of the randomized pemetrexed + cisplatin vs. cisplatin trial using the LCSS-meso instrument. Proc Am Soc Clin Oncol 2003; 22: 621 (abstr 2496).
47. Hughes A, Calvert P, Azzabi A, Plummer R, Johnson R, Rusthoven J et al. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 2002; 20: 3533-44.
48. Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 2006; 24: 1443-8.
49. Steele JP, Shamash J, Evans MT, Gower NH, Tischkowitz MD, Rudd RM. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 2000; 18: 3912-7.
50. Muers MF, Fisher P, Snee M, Lowry E, O'Brien ME, Peake M et al. A randomized phase III trial of active symptom control (ASC) with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma: First results of the Medical Research Council (MRC)/ British Thoracic Society (BTS) MS01 trial. J Clin Oncol 2007; ASCO Annual Meeting Proceedings Part I. Vol 25(18S): LBA7525.
51. Janne PA, Simon GR, Langer CJ, Taub RN, Dowlati A, Fidias P et al. An Update of Pemetrexed (P) Plus Gemcitabine (G) as Front-Line Chemotherapy for Patients (pts) with Malignant Pleural Mesothelioma (MPM): A Phase II Clinical Trial. Proc Am Soc Clin Oncol 2005; 23 (16S): Abs 7067.
52. Scagliotti GV, Shin DM, Kindler HL, Vasconcelles MJ, Keppler U, Manegold C et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003; 21: 1556-61.
53. Karrison T, Kindler HL, Gandara DR, Lu C, Guterz TL, Nichols K et al. Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM). J Clin Oncol 2007; ASCO Annual Meeting Proceedings Part I, Vol 25(18S):ABstr 7526.
54. Kindler HL. Moving beyond chemotherapy: Novel cytostatic agents for malignant mesothelioma. Lung Cancer 2004; 45 (Suppl.): S125-7.
55. Giaccone G, O'Brien ME, Byrne MJ, Bard M, Kaukel E, Smit B. Phase II trial of ZD0473 as second-line therapy in mesothelioma. Eur J Cancer 2002; 38 (Suppl.): S19-24.
56. Porta C, Zimatore M, Bonomi L, Imarisio I, Paglino C, Sartore-Bianchi A et al. Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients. Lung Cancer 2005; 48: 429-34.
57. Fizazi K, Doubre H, Le Chevalier T, Riviere A, Viala J, Daniel C et al. Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: Results of a phase II study. J Clin Oncol 2003; 21: 349-54.
58. Manegold C, Symanowski J, Gatzemeier U, Von Pawel J, Kortsik C, Nackaerts K et al. Secondary (post-study) chemotherapy in the phase III study of pemetrexed+cisplatin vs cisplatin in malignant pleural mesothelioma is associated with longer survival. Proc Am Soc Clin Oncol 2003; 22: 667 (abstr 2684).
59. Kindler HL, Millard F, Herndon JE 2nd, Vogelzang NJ, Suzuki Y, Green MR. Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B. Lung Cancer 2001; 31: 311-17.
60. van Meerbeeck JP, Baas P, Debruyne C, Groen HJ, Manegold C, Ardizzoni A et al. A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Cancer 1999; 85: 2577-82.
61. Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hazel G, Buck M et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: A phase II study. J Clin Oncol 1999; 17: 25-30.
62. Edwards JG, Swinson DEB, Jones JL, Waller DA, O'Byrne KJ. EGFR expression: Associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer 2006; 54: 399-407.
63. Destro A, Ceresoli GL, Falleni M, Zucali PA, Morenghi E, Bianchi P et al. EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer 2006; 51: 207-15.
64. Dazzi H, Hasleton PS, Thatcher N, Wilkes S, Swindell R, Chatterjee AK. Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br J Cancer 1990; 61: 924-6.
65. Janssen YM, Heintz NH, Mossman BT. Induction of c-fos and c-jun proto-oncogene expression by asbestos is ameliorated by N-acetyl-L-cysteine in mesothelial cells. Cancer Res 1995; 55: 2085-9.
66. Heintz NH, Janssen YM, Mossman BT. Persistent induction of c-fos and c-jun expression by asbestos. Proc Natl Acad Sci 1993; 90: 3299-303.
67. Dai Y, Bedrossian CWM, Michael CW. The expression pattern of beta-catenin in mesothelial proliferative lesions and its diagnostic utilities. Diagnostic Cytopathology 2005; 33: 320-4.
68. Batra S, Shi Y, Kuchenbecker KM, He B, Reguart N, Mikami I et al. Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma. Biochemical & Biophysical Research Communications. 2006; 342: 1228-32.
69. Mazieres J, You L, He B, Xu Z, Twogood S, Lee AY et al. Wnt2 as a new therapeutic target in malignant pleural mesothelioma. International Journal of Cancer. 2005; 117: 326-32.
70. 5Uematsu K, Kanazawa S, You L, He B, Xu Z, Li K et al. Wnt pathway activation in mesothelioma: Evidence of Dishevelled overexpression and transcriptional activity of beta-catenin. Cancer Res 2003; 63: 4547-51.
71. Soini Y, Kinnula V, Kaarteenaho-Wiik R, Kurttila E, Linnainmaa K, Paakko P. Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X, and bax in malignant mesothelioma. Clinical Cancer Research 1999; 5: 3508-15.
72. Narasimhan SR, Yang L, Gerwin BI, Broaddus VC. Resistance of pleural mesothelioma cell lines to apoptosis: Relation to expression of Bcl-2 and Bax. American Journal of Physiology 1998; 275: L165-71.
73. Cao XX, Mohuiddin I, Ece F, McConkey DJ, Smythe WR. Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma. American Journal of Respiratory Cell & Molecular Biology 2001; 25: 562-8.